A PROTEIN which helps breast cancer tumours survive could be targeted with a new type of drug that is already being tested for other cancers, research suggests.
The protein, known as MCL-1, helps breast cancer cells survive by hindering their natural ability to die.
This process, called apoptosis, is the body’s way of getting rid of unwanted, harmful or damaged cells.
However, cancer cells can become expert at avoiding apoptosis in order to survive.
The new study, from the University of Glasgow, confirms that breast cancer tumours rely on MCL-1 to help them grow more aggressively.
It also found that breast cancer stem cells, which are thought to be responsible for the disease spreading and becoming resistant to treatments, are especially dependent on MCL-1 for growth and survival.
A new class of compounds called BH3 mimetics, which target the MCL-1 protein, could be used to “kick-start” apoptosis in breast cancer cells, slowing the growth of tumours, experts behind the new study say. Through their research in mice, they were able to show that the growth of tumours was significantly slowed down with BH3 mimetic drugs.
BH3 mimetics are already undergoing clinical trials for some blood cancers.
Professor Stephen Tait, who led the new study at the Institute of Cancer Sciences at the University of Glasgow, said: “Our study further highlights the importance of MCL-1 protein in breast cancer.
“Our demonstration that MCL-1 acts in breast cancer by keeping cells alive (as opposed to other MCL-1 functions) is important, because drugs that target MCL-1 survival function are now in clinical development.
“The next steps will be to determine the effectiveness of
MCL-1-targeting drugs that are in clinical development to treat breast cancer in combination with existing therapies.”
The study was funded by the charity Breast Cancer Now in partnership with the Scottish Government’s Chief Scientist Office.
Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, said: “With around 55,000 women being diagnosed with breast cancer
every year in the UK, we urgently need to find new ways to treat people and prevent deaths from this devastating disease.”
The study was published in the journal Cell Death & Differentiation.
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules here